Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis - Concepedia

Concepedia

Publication | Closed Access

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis

166

Citations

28

References

2007

Year

Dennis A. Revicki, Mary Kaye Willian, J.‐H. Saurat, Kim Papp, J.‐P. Ortonne, Cora Sexton, A. Camez

British Journal of Dermatology

Abstract

Adalimumab was efficacious in improving dermatology-specific HRQOL, disease control and symptom outcomes in patients with moderate to severe psoriasis.

References

	Year	Citations

Page 1